Conatus Pharmaceuticals (CNAT) Tops Q4 EPS by 2c

Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q4 EPS of ($0.15), $0.02 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $8.8 million versus the consensus estimate of $9.49 million.

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery